Circumscribed Nevoid Angiokeratoma: Report of Three New Cases
Journal Title: Journal of Dermatology Research - Year 2023, Vol 4, Issue 3
Abstract
The angiokeratomas are vascular malformations histologically characterized by the presence of dilated surface capillaries with overlying hyperkeratosis, there are five types clinically recognizable. The nevoid circumscriptum angiokeratoma is an unusual type of angiokeratoma located mainly in buttocks or thighs showing a unilateral distribution. We present three new female cases of this uncommon pathology.
Authors and Affiliations
Eduardo Garzón Aldás, Jennifer Granizo Rubio, Xavier Garzón Garzón
Chemokine Ligand-Receptor Axes for Therapeutic Targeting During Skin Regeneration
Chemokines and their cognate receptor interactions regulate the balance between pro-inflammatory and anti-inflammatory signals to support the physiological functions of the skin. Chemokines also regulate the process of a...
Improvements in Skin and Nail Psoriasis are Positively Correlated across Systemic Psoriasis Therapies
Objective: For clinical scenarios where patients have moderate to severe psoriasis and nail psoriasis, knowing whether skin response is correlated with nail response would provide insight into the relationship between ps...
Acral Cutaneous Manifestations during COVID-19 Outbreak
We describe a patient with multiple cutaneous lesions resembling chilblains affecting her feet. She was one of 5 patients with these findings that we have seen during the last week, 4 of them in Venice, Italy, one of t...
Nifuroxazide Erythema Pigmented Fixed: A Side Effect to Be Aware Off
Erythema Pigmentum Fixata (EPF) is a delayed-type toxidermia. It manifests itself within 48 h after the re-introduction of a drug by the appearance of a recurrent rash, leaving a residual hyperpigmentation [1]. We report...
Comparative Study Between Two Protocols of Rituximab in Pemphigus: About 63 Cases
Background: Pemphigus is a rare autoimmune mucocutaneous bullous disease. It includes pemphigus vulgaris and pemphigus superficial. Rituximab is an antibody that targets CD-20 molecules on B-cells and has been approved a...